DGAP-News: Oxford Immunotec to Present at the 32nd Annual J.P. Morgan Healthcare Conference

        Print
| Source: EQS Group AG
DGAP-News: Oxford Immunotec /
Oxford Immunotec to Present at the 32nd Annual J.P. Morgan Healthcare
Conference

08.01.2014 / 19:26

---------------------------------------------------------------------

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2014-01-08 19:26 CET (GLOBE
NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that Peter
Wrighton-Smith Ph.D., Chief Executive Officer, and Rick Altieri, Chief
Financial Officer, will present at the 32nd Annual J.P. Morgan Healthcare
Conference at the Westin St. Francis Hotel in San Francisco, California on
Thursday, January 16, 2014 at 12:30 pm PT. 

A live webcast of the presentation will be available online from the investor
relations page of the Company's corporate website at www.oxfordimmunotec.com.
After the live webcast, the presentation will remain available on the website
for 90 days. 

                                     -Ends-

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system,
and are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune
diseases. The Company's lead product developed using the T-SPOT technology
platform is the T-SPOT.TB test, which is used to test for latent tuberculosis
infection. The T-SPOT.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market approval from the
Food and Drug Administration, in Europe, where it has obtained a CE mark, as
well as Japan and China. The Company is headquartered near Oxford, UK and in
Marlborough, MA. 

Additional information can be found at www.oxfordimmunotec.com.

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: +1 (508) 481-4648
raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
oxfordimmunotec@westwicke.com

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

08.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English           
Company:     Oxford Immunotec  
 
 
             Großbritannien   
ISIN:        GB00BGFBB958      
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
247340 08.01.2014